Intact Investment Management Inc. Purchases 46,400 Shares of Merck & Co., Inc. (NYSE:MRK)

Intact Investment Management Inc. increased its position in Merck & Co., Inc. (NYSE:MRKFree Report) by 27.9% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 212,600 shares of the company’s stock after acquiring an additional 46,400 shares during the quarter. Intact Investment Management Inc.’s holdings in Merck & Co., Inc. were worth $21,149,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of the company. State Street Corp lifted its position in Merck & Co., Inc. by 1.3% during the third quarter. State Street Corp now owns 119,026,412 shares of the company’s stock valued at $13,606,360,000 after purchasing an additional 1,536,474 shares during the last quarter. Wellington Management Group LLP lifted its position in Merck & Co., Inc. by 4.6% during the third quarter. Wellington Management Group LLP now owns 75,809,383 shares of the company’s stock valued at $8,608,914,000 after purchasing an additional 3,327,404 shares during the last quarter. Geode Capital Management LLC lifted its position in Merck & Co., Inc. by 3.7% during the third quarter. Geode Capital Management LLC now owns 59,155,004 shares of the company’s stock valued at $6,696,060,000 after purchasing an additional 2,134,296 shares during the last quarter. Bank of New York Mellon Corp lifted its position in Merck & Co., Inc. by 29.7% during the fourth quarter. Bank of New York Mellon Corp now owns 24,213,537 shares of the company’s stock valued at $2,408,763,000 after purchasing an additional 5,550,824 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its position in Merck & Co., Inc. by 7.0% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 20,125,171 shares of the company’s stock valued at $2,002,052,000 after purchasing an additional 1,317,878 shares during the last quarter. 76.07% of the stock is currently owned by institutional investors.

Merck & Co., Inc. Stock Up 1.4 %

NYSE MRK opened at $94.64 on Friday. The company has a debt-to-equity ratio of 0.79, a current ratio of 1.36 and a quick ratio of 1.15. The stock has a market capitalization of $239.07 billion, a PE ratio of 14.06, a PEG ratio of 0.77 and a beta of 0.35. Merck & Co., Inc. has a 1 year low of $81.04 and a 1 year high of $134.63. The business’s 50-day moving average is $93.66 and its 200 day moving average is $102.14.

Merck & Co., Inc. (NYSE:MRKGet Free Report) last posted its earnings results on Tuesday, February 4th. The company reported $1.72 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.85 by ($0.13). The business had revenue of $15.62 billion during the quarter, compared to the consensus estimate of $15.51 billion. Merck & Co., Inc. had a return on equity of 45.35% and a net margin of 26.67%. The firm’s revenue for the quarter was up 6.8% compared to the same quarter last year. During the same period in the previous year, the business earned $0.03 earnings per share. Sell-side analysts forecast that Merck & Co., Inc. will post 9.01 earnings per share for the current year.

Merck & Co., Inc. announced that its Board of Directors has approved a stock buyback program on Tuesday, January 28th that authorizes the company to repurchase $10.00 billion in shares. This repurchase authorization authorizes the company to repurchase up to 4.1% of its stock through open market purchases. Stock repurchase programs are typically a sign that the company’s board of directors believes its stock is undervalued.

Merck & Co., Inc. Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, April 7th. Shareholders of record on Monday, March 17th will be issued a $0.81 dividend. The ex-dividend date of this dividend is Monday, March 17th. This represents a $3.24 annualized dividend and a yield of 3.42%. Merck & Co., Inc.’s dividend payout ratio (DPR) is presently 48.14%.

Insiders Place Their Bets

In related news, Director Inge G. Thulin acquired 2,833 shares of the stock in a transaction on Thursday, February 6th. The stock was acquired at an average cost of $88.25 per share, for a total transaction of $250,012.25. Following the completion of the acquisition, the director now directly owns 2,933 shares of the company’s stock, valued at approximately $258,837.25. This represents a 2,833.00 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Cristal N. Downing sold 2,361 shares of the firm’s stock in a transaction dated Thursday, February 6th. The stock was sold at an average price of $88.76, for a total transaction of $209,562.36. Following the completion of the sale, the insider now owns 7,085 shares of the company’s stock, valued at $628,864.60. This trade represents a 24.99 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.09% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several equities research analysts have issued reports on MRK shares. Leerink Partners dropped their target price on shares of Merck & Co., Inc. from $136.00 to $119.00 and set an “outperform” rating for the company in a research report on Monday, January 13th. Deutsche Bank Aktiengesellschaft lowered shares of Merck & Co., Inc. from a “buy” rating to a “hold” rating and dropped their target price for the company from $128.00 to $105.00 in a research report on Tuesday, February 18th. BMO Capital Markets dropped their target price on shares of Merck & Co., Inc. from $105.00 to $96.00 and set a “market perform” rating for the company in a research report on Wednesday, February 5th. Truist Financial reaffirmed a “hold” rating and issued a $110.00 price objective (down previously from $130.00) on shares of Merck & Co., Inc. in a research note on Wednesday, January 8th. Finally, Wolfe Research began coverage on shares of Merck & Co., Inc. in a report on Friday, November 15th. They set a “peer perform” rating on the stock. Eleven investment analysts have rated the stock with a hold rating, nine have assigned a buy rating and three have given a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $117.12.

Read Our Latest Analysis on MRK

About Merck & Co., Inc.

(Free Report)

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.

Featured Articles

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRKFree Report).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.